Company Description
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors.
The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials.
Portage Biotech Inc. is based in Tortola, British Virgin Islands.
| Country | British Virgin Islands |
| Founded | 1973 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Alexander Pickett |
Contact Details
Address: Clarence Thomas Building, P.O. Box 4649 Tortola, VG1110 British Virgin Islands | |
| Phone | 203 221 7378 |
| Website | portagebiotech.com |
Stock Details
| Ticker Symbol | PRTG |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001095435 |
| CUSIP Number | G7185A128 |
| ISIN Number | VGG7185A1286 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | 424B3 | Prospectus |
| Feb 12, 2025 | 6-K | Report of foreign issuer |
| Jan 31, 2025 | SCHEDULE 13D/A | Filing |
| Jan 31, 2025 | SCHEDULE 13D/A | Filing |
| Jan 30, 2025 | 424B3 | Prospectus |
| Jan 30, 2025 | 6-K | Report of foreign issuer |
| Jan 6, 2025 | 424B3 | Prospectus |
| Jan 6, 2025 | 6-K | Report of foreign issuer |
| Dec 19, 2024 | SCHEDULE 13D/A | Filing |
| Dec 17, 2024 | 424B3 | Prospectus |